216 related articles for article (PubMed ID: 37532597)
1. Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.
Zhang D; Gu M
Eur J Cancer; 2023 Sep; 191():112979. PubMed ID: 37532597
[No Abstract] [Full Text] [Related]
2. Response to letter entitled: Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.
van Hulst AM; Grootenhuis MA; van den Akker ELT; van den Heuvel-Eibrink MM
Eur J Cancer; 2023 Sep; 191():112980. PubMed ID: 37574396
[No Abstract] [Full Text] [Related]
3. Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.
van Hulst AM; van den Akker ELT; Verwaaijen EJ; Fiocco M; Rensen N; van Litsenburg RRL; Pluijm SMF; Zwaan CM; van Santen HM; Pieters R; Evers AWM; Grootenhuis MA; van den Heuvel-Eibrink MM
Eur J Cancer; 2023 Jul; 187():124-133. PubMed ID: 37149961
[TBL] [Abstract][Full Text] [Related]
4. Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.
van Hulst AM; Verwaaijen EJ; Fiocco MF; Pluijm SMF; Grootenhuis MA; Pieters R; van den Akker ELT; van den Heuvel-Eibrink MM
BMC Pediatr; 2021 Sep; 21(1):427. PubMed ID: 34579671
[TBL] [Abstract][Full Text] [Related]
5. Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial.
Warris LT; van den Heuvel-Eibrink MM; Aarsen FK; Pluijm SM; Bierings MB; van den Bos C; Zwaan CM; Thygesen HH; Tissing WJ; Veening MA; Pieters R; van den Akker EL
J Clin Oncol; 2016 Jul; 34(19):2287-93. PubMed ID: 27161966
[TBL] [Abstract][Full Text] [Related]
6. Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia.
Warris LT; van den Akker EL; Aarsen FK; Bierings MB; van den Bos C; Tissing WJ; Sassen SD; Veening MA; Zwaan CM; Pieters R; van den Heuvel-Eibrink MM
Psychoneuroendocrinology; 2016 Oct; 72():190-5. PubMed ID: 27448086
[TBL] [Abstract][Full Text] [Related]
7. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
[TBL] [Abstract][Full Text] [Related]
8. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for adrenal insufficiency in those treated for all: tapering glucocorticoids before abrupt discontinuation.
Felner EI
J Pediatr Hematol Oncol; 2011 Aug; 33(6):406-8. PubMed ID: 21792034
[No Abstract] [Full Text] [Related]
10. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Mrakotsky CM; Silverman LB; Dahlberg SE; Alyman MC; Sands SA; Queally JT; Miller TP; Cranston A; Neuberg DS; Sallan SE; Waber DP
Pediatr Blood Cancer; 2011 Sep; 57(3):492-8. PubMed ID: 21560226
[TBL] [Abstract][Full Text] [Related]
11. Duration of adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia.
Vestergaard TR; Juul A; Lausten-Thomsen U; Lausen B; Hjalgrim H; Kvist TK; Andersen EW; Schmiegelow K
J Pediatr Hematol Oncol; 2011 Aug; 33(6):442-9. PubMed ID: 21792040
[TBL] [Abstract][Full Text] [Related]
12. Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review.
Warris LT; van den Heuvel-Eibrink MM; den Hoed MA; Aarsen FK; Pieters R; van den Akker EL
Pediatr Blood Cancer; 2014 Jul; 61(7):1313-8. PubMed ID: 24532490
[TBL] [Abstract][Full Text] [Related]
13. Double-blind crossover study of chlorpromazine and lorazepam in the treatment of behavioral problems during treatment of children with acute lymphoblastic leukaemia receiving glucocorticoids.
Pelletier G; Lacroix Y; Moghrabi A; Robaey P
Med Pediatr Oncol; 2000 Apr; 34(4):276-7. PubMed ID: 10742070
[No Abstract] [Full Text] [Related]
14. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
[TBL] [Abstract][Full Text] [Related]
15. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
16. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Landmann E; Burkhardt B; Zimmermann M; Meyer U; Woessmann W; Klapper W; Wrobel G; Rosolen A; Pillon M; Escherich G; Attarbaschi A; Beishuizen A; Mellgren K; Wynn R; Ratei R; Plesa A; Schrappe M; Reiter A; Bergeron C; Patte C; Bertrand Y
Haematologica; 2017 Dec; 102(12):2086-2096. PubMed ID: 28983060
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008727. PubMed ID: 29106702
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone.
Kuperman H; Odone Filho V; Cristofani LM; Assis de Almeida MT; Setian N; Damiani D
Horm Res Paediatr; 2012; 78(2):73-80. PubMed ID: 22922775
[TBL] [Abstract][Full Text] [Related]
19. Steroid-induced alterations of behaviour during treatment for acute lymphoblastic leukaemia: a sibling's description.
Wei C
Arch Dis Child; 2011 Mar; 96(3):251. PubMed ID: 21252062
[No Abstract] [Full Text] [Related]
20. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
Einaudi S; Bertorello N; Masera N; Farinasso L; Barisone E; Rizzari C; Corrias A; Villa A; Riva F; Saracco P; Pastore G
Pediatr Blood Cancer; 2008 Mar; 50(3):537-41. PubMed ID: 17828747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
